2. Search Result
Search Result
Results for "

Cognitive impairment

" in MedChemExpress (MCE) Product Catalog:

224

Inhibitors & Agonists

3

Fluorescent Dyes

2

Biochemical Assay Reagents

4

Peptides

2

Inhibitory Antibodies

35

Natural
Products

11

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0045
    Ginsenoside Rg1
    Maximum Cited Publications
    15 Publications Verification

    Panaxoside A; Panaxoside Rg1

    		 Amyloid-β NF-κB Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
    Ginsenoside Rg1
  • HY-103157
    PD146176
    5+ Cited Publications

    NSC168807

    		 Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176
  • HY-W004260
    Arachidic acid
    3 Publications Verification

    Eicosanoic acid

    		 Endogenous Metabolite Neurological Disease
    Arachidic acid is an orally bioavailable membrane fluidity modulator and receptor/ion channel effector. Arachidic acid does not activate arachidonic acid-sensitive K + channels in rat midbrain and hypothalamic neurons. Arachidic acid alleviates age-related spatial cognitive impairment. Arachidic acid is applicable for research related to age-related spatial cognitive impairment .
    Arachidic acid
  • HY-W019894
    Manganese chloride
    1 Publications Verification

    Manganese dichloride

    		 Biochemical Assay Reagents Apoptosis mTOR Cardiovascular Disease Neurological Disease
    Manganese chloride is an orally active MRI liver contrast agent. Manganese chloride induces Apoptosis and activates the mTOR signaling pathway. Manganese chloride induces cognitive impairment, promotes hematopoietic recovery, and reduces radiation-induced bone marrow and brain damage. It can be used for the study of renal impairment .
    Manganese chloride
  • HY-B0463
    Clomiphene citrate
    5 Publications Verification

    Clomifene citrate

    		 Estrogen Receptor/ERR Neurological Disease Endocrinology Cancer
    Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .
    Clomiphene citrate
  • HY-14258
    Escitalopram
    10+ Cited Publications

    (S)-Citalopram; (S)-(+)-Citalopram

    		 Serotonin Transporter Neurological Disease
    Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
    Escitalopram
  • HY-N7109
    Erucic acid
    2 Publications Verification

    		 PI3K Endogenous Metabolite Neurological Disease
    Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia .
    Erucic acid
  • HY-14258A
    Escitalopram oxalate
    10+ Cited Publications

    (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate

    		 Serotonin Transporter Neurological Disease Cancer
    Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
    Escitalopram oxalate
  • HY-101484A
    NE-100 hydrochloride
    1 Publications Verification

    		 Sigma Receptor ATF6 Neurological Disease
    NE-100 hydrochloride is an orally active and selective sigma-1 receptor antagonist with an IC50 of 4.16 nM. NE-100 hydrochloride can improve cognitive impairment and has neuroprotective and antipsychotic activities. NE-100 hydrochloride can be used for research on nervous system diseases .
    NE-100 hydrochloride
  • HY-N2195
    Nootkatone
    4 Publications Verification

    (+)-Nootkatone

    		 Environmental Pollutants Interleukin Related TNF Receptor Neurological Disease
    Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects . Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease .
    Nootkatone
  • HY-10933
    CX516
    2 Publications Verification

    BDP 12

    		 iGluR Neurological Disease
    CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
    CX516
  • HY-N2189
    Swertisin
    2 Publications Verification

    		 Adenosine Receptor HBV SGLT Infection Neurological Disease Inflammation/Immunology
    Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice .
    Swertisin
  • HY-116451
    PF-04859989 hydrochloride
    1 Publications Verification

    		 Aminotransferases (Transaminases) Neurological Disease
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .
    PF-04859989 hydrochloride
  • HY-N7981
    Pratensein
    1 Publications Verification

    		 NF-κB Neurological Disease
    Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .
    Pratensein
  • HY-17550
    Sunifiram

    DM-235

    		 iGluR Neurological Disease
    Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .
    Sunifiram
  • HY-17553
    Coluracetam
    3 Publications Verification

    MKC-231

    		 iGluR Neurological Disease
    Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .
    Coluracetam
  • HY-168894
    CT-1

    		Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .
    CT-1
  • HY-132806
    Alogabat

    RG-7816; RO-7017773

    		 GABA Receptor Neurological Disease
    Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
    Alogabat
  • HY-17455
    Pramiracetam

    CI-879 free base

    		 Prolyl Endopeptidase (PREP) Neurological Disease
    Pramiracetam (CI-879 free base) is a PREP (prolyl endopeptidase) inhibitor. Pramiracetam improves cognitive impairment caused by traumatic brain injury. Pramiracetam can be used in the study of neurodegenerative diseases .
    Pramiracetam
  • HY-107111
    GSK1034702

    		mAChR Neurological Disease
    GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC50=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .
    GSK1034702
  • HY-121035
    7BIO

    7-Bromoindirubin-3-Oxime

    		 CDK GSK-3 Neurological Disease
    7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
    7BIO
  • HY-17549
    Adrafinil

    CRL 40028

    		 Adrenergic Receptor Neurological Disease
    Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
    Adrafinil
  • HY-N8903
    Mumefural

    		Integrin NF-κB Toll-like Receptor (TLR) TNF Receptor Cardiovascular Disease Neurological Disease
    Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment .
    Mumefural
  • HY-105066
    Davunetide
    1 Publications Verification

    		 Microtubule/Tubulin Amyloid-β Neurological Disease
    Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .
    Davunetide
  • HY-14759
    Aleplasinin

    PAZ-417

    		 PAI-1 Amyloid-β Neurological Disease
    Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC50=655 nM). Aleplastinin activates the tissue type plasminogen activator (tPA)/fibrinolysis cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease .
    Aleplasinin
  • HY-W166297
    Esculin sesquihydrate
    5 Publications Verification

    		 p38 MAPK Cancer
    Esculin sesquihydrate, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin sesquihydrate ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts anti?oxidative stress and anti?inflammatory effects, via the MAPK signaling pathway .
    Esculin sesquihydrate
  • HY-P99959
    Unasnemab

    MT-3921; rH116A3

    		 TGF-β Receptor Neurological Disease
    Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
    Unasnemab
  • HY-102083
    BRD4884

    		HDAC Neurological Disease
    BRD4884 is a potent and brain-penetrant HDAC inhibitor with IC50 values of 29 nM, 62 nM, and 1090 nM for HDAC1, HDAC2, and HDAC3, respectively. BRD4884 can be used for the study of cognitive impairment .
    BRD4884
  • HY-118363
    Lu AE51090

    		mAChR Neurological Disease
    Lu AE51090 is selective muscarinic M1 receptor agonist with blood-brain barrier penetration. Lu AE51090 activates human M1 receptor with EC50 of 61 nM, while showing no significant agonism at M2-M5 receptors. Lu AE51090 exerts procognitive effects in mice. Lu AE51090 can be used for the study of Alzheimer’s disease (AD) and cognitive impairment associated with schizophrenia (CIAS) .
    Lu AE51090
  • HY-153763
    PROT-IN-1

    		Amino acid Transporter Neurological Disease
    PROT-IN-1 is a PROT inhibitor (IC50: 1.48 μM). PROT-IN-1 is applicable to research related to cognitive impairment .
    PROT-IN-1
  • HY-N4268
    Tenuifoliside B

    		Others Neurological Disease
    Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .
    Tenuifoliside B
  • HY-139973
    OAB-14

    		Amyloid-β Neurological Disease
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
    OAB-14
  • HY-113970A
    Nebracetam hydrochloride

    WEB 1881 FU hydrochloride

    		 mAChR Calcium Channel Neurological Disease
    Nebracetam (WEB 1881 FU) hydrochloride is an orally active M1 muscarinic receptor agonist. Nebracetam hydrochloride can induce an increase in intracellular Ca 2+ concentration, with an EC50 value of 1.59 mM. Nebracetam hydrochloride exhibits neuroprotective activity and the ability to improve cognitive impairment. Nebracetam hydrochloride can be used in the research of neurological diseases such as Alzheimer's disease .
    Nebracetam hydrochloride
  • HY-B0463R
    Clomiphene citrate (Standard)

    Clomifene citrate (Standard)

    		 Reference Standards Estrogen Receptor/ERR Neurological Disease Endocrinology Cancer
    Clomiphene (citrate) (Standard) is the analytical standard of Clomiphene (citrate). This product is intended for research and analytical applications. Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .
    Clomiphene citrate (Standard)
  • HY-123280
    SCH 54388

    		Drug Metabolite Neurological Disease
    SCH 54388 is an orally active metabolite of Felbamate (HY-B0184). SCH 54388 significantly attenuates the functional impairment effects induced by Scopolamine (HY-N0296) or Dizocilpine (HY-15084B). SCH 54388 can be used in research related to cognitive impairment .
    SCH 54388
  • HY-W001273
    Pramiracetam sulfate

    CI-879 sulfate

    		 Prolyl Endopeptidase (PREP) Neurological Disease
    Pramiracetam (CI-879) sulfate Pramiracetam is a PREP (prolyl endopeptidase) inhibitor. Pramiracetam sulfate improves cognitive impairment caused by traumatic brain injury. Pramiracetam sulfate can be used in the study of neurodegenerative diseases .
    Pramiracetam sulfate
  • HY-110176
    ASP2535

    		GlyT Neurological Disease
    ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .
    ASP2535
  • HY-N2195R
    Nootkatone (Standard)

    (+)-Nootkatone (Standard)

    		 Reference Standards Interleukin Related TNF Receptor Neurological Disease
    Nootkatone (Standard) is the analytical standard of Nootkatone. This product is intended for research and analytical applications. Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects[1]. Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease[2].
    Nootkatone (Standard)
  • HY-113745
    LX-6171

    		Amino acid Transporter Neurological Disease
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia .
    LX-6171
  • HY-146351
    HDAC-IN-38

    		HDAC Neurological Disease
    HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .
    HDAC-IN-38
  • HY-156634
    Risevistinel

    NYX-783

    		 iGluR Neurological Disease
    Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
    Risevistinel
  • HY-19092
    YM-796 dihydroxybutanedioate

    		mAChR Neurological Disease
    YM-796 dihydroxybutanedioate is a selective muscarinic M1 receptor agonist. YM-796 dihydroxybutanedioate can improve cognitive impairment and reduce amyloid plaque deposition. YM-796 dihydroxybutanedioate can be used in the research of cognitive impairment diseases such as Alzheimer's disease .
    YM-796 dihydroxybutanedioate
  • HY-156626
    Nevadistinel

    NYX-458; NYX-3054

    		 iGluR Neurological Disease
    Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
    Nevadistinel
  • HY-19668
    SGS-518

    		5-HT Receptor Neurological Disease
    SGS-518 is a selective 5-HT6R antagonist. SGS518 can be used for the research of cognitive impairments such as amnesia, anxiety and depression, and it is effective in protecting mouse retina at high doses .
    SGS-518
  • HY-120641
    BMS-955829

    		mGluR Neurological Disease
    BMS-955829 is an orally active and selective mGluR5 positive allosteric modulator with an EC50 of 2.6 nM. BMS-955829 has no intrinsic agonist activity and a low glutamate fold shift (2.4). BMS-955829 can effectively improve cognitive and executive function deficits in rodents. BMS-955829 can be used in the research of cognitive impairment diseases such as schizophrenia .
    BMS-955829
  • HY-14555
    S 33138

    		Dopamine Receptor Neurological Disease
    S33138 is a D3 receptor antagonist. S33138 inhibits addiction in animal models of addiction. S33138 reduces cognitive impairment in rodent and primate models of schizophrenia and Parkinson's disease. S33138 can be used in research on neurological disorders such as schizophrenia and Parkinson's disease .
    S 33138
  • HY-113967
    PF-04859989

    		Aminotransferases (Transaminases) Neurological Disease
    PF-04859989 is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .
    PF-04859989
  • HY-W062702
    BMS-933043

    		nAChR Neurological Disease
    BMS-933043 is a potent and selective α7 nACh receptor partial agonist. BMS-933043 attenuates the cognitive impairment in mice and can be utilized in research related to cognitive dysfunction in schizophrenia .
    BMS-933043
  • HY-114586
    L-158809

    		Angiotensin Receptor Cancer
    L-158809 is an angiotensin type 1 (AT1) receptor antagonist that prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. L-158809 is promising for research of brain tumor .
    L-158809
  • HY-W714110
    UH 301 hydrochloride

    		5-HT Receptor Neurological Disease
    UH 301 hydrochloride is a 5-HT1A receptor antagonist. UH 301 hydrochloride modulates consolidation of learning in normal and cognitively impaired rats. UH 301 hydrochloride can be used for Alzheimer’s disease and amnesia research .
    UH 301 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: